TB-500 Research Overview: Thymosin Beta-4 Mechanisms and Literature
This article is a preclinical, mechanistic research summary — it is not a guide to human use. It contains no dosing, administration, protocol or personal-use information, and none should be inferred from it.
TB-500 is often discussed as though it were interchangeable with thymosin beta-4. The published literature does not support that shortcut, and understanding the distinction is the most useful thing a researcher can take from a literature overview of this compound.
What is TB-500?
TB-500 is a synthetic peptide corresponding to the actin-binding domain — the LKKTETQ region — of thymosin beta-4, a naturally occurring 43-amino-acid protein present in most human cells. Thymosin beta-4 itself has been studied since the 1980s; TB-500 represents the short functional fragment rather than the full protein.
Proposed mechanism
The mechanism described across the literature is sequestration of monomeric G-actin. Actin monomer availability is central to cytoskeletal reorganisation and therefore to cell migration in experimental systems.
Notably, this single mechanism underlies most of the broader research literature on cell migration, angiogenesis and tissue repair signalling attributed to thymosin beta-4. The apparent breadth of that literature reflects the downstream reach of one actin-binding role, not multiple independently characterised mechanisms — and all of it sits in preclinical model systems rather than established human effect.
What the current evidence shows
A 2026 scoping review published by MDPI mapping the TB4/TB-500 literature reports an evidence base weighted toward in-vitro and mixed preclinical designs. Two findings from that mapping matter most:
- Most studies evaluate full thymosin beta-4 rather than TB-500 specifically, so conclusions are frequently extrapolated across two distinct molecules.
- Direct human evidence for TB-500 itself was limited to a single included study.
Where thymosin beta-4 research is most clinically advanced is in ocular and corneal work — again concerning the full protein rather than the TB-500 fragment.
On the regulatory side, the FDA has listed the TB4 fragment among substances presenting compounding safety concerns due to limited human exposure data, and WADA classifies TB4/TB-500 as prohibited substances. These points are stated factually and are not product claims.
Is TB-500 legal in the UK?
TB-500 is not a controlled drug under the Misuse of Drugs Act 1971, so it can be supplied to and held by UK laboratories as a research chemical for in-vitro work.
It holds no MHRA marketing authorisation. Under the Human Medicines Regulations 2012 it cannot lawfully be sold, advertised or supplied in the UK as a medicine, supplement or veterinary product, or for administration to humans or animals — including horses and dogs, where TB-500 is frequently discussed and where the Veterinary Medicines Regulations apply. WADA classifies TB4/TB-500 as prohibited, and UK Anti-Doping enforces that list in sport.
Is TB-500 safe?
No human safety profile has been established. The 2026 MDPI scoping review found the literature weighted toward in-vitro and mixed preclinical designs, with direct TB-500 human evidence limited to a single included study — and the FDA has listed the TB4 fragment among substances presenting compounding safety concerns precisely because human exposure data is limited.
Treat it in the laboratory as an uncharacterised research chemical: trained personnel, appropriate PPE, lyophilised storage protected from light, controlled reconstitution, and institutional chemical waste disposal. It must never be administered to humans or animals.
Sourcing TB-500 in the UK
For UK laboratories the deciding factors are provenance and documentation: a batch-specific certificate of analysis with HPLC purity and mass-spectrometry identity, a batch code printed on the vial that matches that certificate, and unambiguous research-use-only labelling.
NXT GEN RESEARCH holds TB-500 in UK stock with 24 hour tracked UK dispatch, and batch documentation can be checked on our batch verification page. All material is supplied for in-vitro laboratory research only.
Research use only disclaimer
Warning — for laboratory research use only
The products offered on this website are research chemicals supplied strictly for in-vitro laboratory research by qualified researchers. They are NOT medicines, dietary supplements, cosmetics, food, or veterinary products, and are HARMFUL if ingested, injected, inhaled, or applied to humans or animals. They MUST NOT be consumed by, or administered to, any human or animal, under any circumstances. Nothing on this page constitutes medical advice or a claim of therapeutic effect. Full terms are set out in our RUO Disclaimer and Terms & Conditions.
Referenced literature
- Scoping review, MDPI, 2026.
- Bock-Marquette et al., Nature, 2004 — ILK/Akt activation pathway.
- Smart et al., Nature, 2007 — epicardial progenitor cell mobilisation in cardiac models.
Frequently asked questions
What is TB-500?
TB-500 is a synthetic peptide corresponding to the actin-binding domain — the LKKTETQ region — of thymosin beta-4, a naturally occurring 43-amino-acid protein present in most human cells and studied since the 1980s.
Is TB-500 legal in the UK?
TB-500 is not a controlled drug under the UK Misuse of Drugs Act 1971 and can be supplied and held in the UK as a research chemical for in-vitro laboratory use. It holds no MHRA marketing authorisation, so it cannot lawfully be sold or supplied in the UK as a medicine, supplement or veterinary product, or for administration to humans or animals. WADA prohibits TB4/TB-500 in sport and UK Anti-Doping enforces that list.
Is TB-500 safe?
No human safety profile has been established. The 2026 MDPI scoping review found the evidence weighted toward in-vitro and mixed preclinical designs with only a single included human study, and the FDA has listed the TB4 fragment among substances presenting compounding safety concerns due to limited human exposure data. It must be handled only as a laboratory reagent and never administered to humans or animals.
Where can I buy TB-500 in the UK?
NXT GEN RESEARCH supplies TB-500 from UK stock to qualified researchers and institutions, with a batch-specific certificate of analysis, a verifiable batch code and 24 hour tracked UK shipping. Material is sold strictly for in-vitro laboratory research use only.
What mechanism is proposed for TB-500?
The primary proposed mechanism is sequestration of monomeric G-actin, a role central to cell migration. This single mechanism underlies most of the broader research literature on cell migration, angiogenesis and tissue repair signalling.
How strong is the current evidence base?
A 2026 scoping review published by MDPI mapping the TB4/TB-500 literature found the evidence weighted toward in-vitro and mixed preclinical designs. Most studies evaluate full thymosin beta-4 rather than TB-500 specifically, and direct TB-500 human evidence was limited to a single included study.
Which research area is most advanced?
Ocular and corneal research is the most clinically advanced area for thymosin beta-4 broadly. That work concerns thymosin beta-4 as a whole rather than the TB-500 fragment specifically.
What is the regulatory status of TB-500?
The FDA has listed the TB4 fragment among substances presenting compounding safety concerns due to limited human exposure data, and WADA classifies TB4/TB-500 as prohibited substances. Material is supplied for in-vitro laboratory research only.
Batch-tested, lyophilised research material with a batch-specific certificate of analysis. Research use only.
View TB-500 product detailsThis guide is intended as general information for research and laboratory audiences. It does not constitute legal, medical, or professional advice.
